44 results about "Very Low-Density Lipoprotein Receptor" patented technology

The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.

It is disclosed here that low density lipoprotein receptor-related protein 5 (LRP5) is a cell surface marker for somatic mammary stem cells and mammary tumor stem cells. The disclosure here provides new tools for enriching somatic mammary stem cells and mammary tumor stem cells. Methods of screening for agents that modulate LRP5 activity, of treating mammary tumor or breast cancer, of monitoring somatic mammary stem cells and mammary tumor stem cells in vivo are also provided, and of assessing prognosis of human breast cancer.

The invention relates to an idiopathic pulmonary fibrosis urine protein marker, and application of the same to diagnosis and prognosis. Specifically, the invention relates to application of a urine protein marker obtained by using an idiopathic pulmonary fibrosis model and mass spectrometry to early-stage diagnosis, pathogenesis monitoring and curative effect assessment of human pulmonary fibrosis. The urine protein marker comprises collagen alpha-1(I) chain, vimentin, protein RUFY3, keratin type-II skeleton 8, a sodium-hydrogen exchange regulation factor NHE-RF2, a threonine synthase sample 2, zinc-actin binding repeat protein 2, low-density lipoprotein receptor-associated protein 4, alpha-11 of a guanine nucleotide binding protein subunit, an alpha-1 chain of tropomyosin, mitochondrial stress-70 protein, NSFL1 cofactor P47, ubiquitin carboxyl-terminal hydrolase isozyme L1, etc.

The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg/kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.

A recombinant vector having an expression cassette is provided which comprises a modified human low density lipoprotein receptor (hLDLR) gene is provided, wherein said hLDLR gene encodes a modified hLDLR comprising (a) one or more of the following amino acid substitutions: L318H, N295D, H306D, V307D, N309A, D310N, L318H, and/or L318D; or (b) an amino acid substitution of any of (a) in combination with one or more of the following amino acid substitutions: K796, K809R and/or C818A. Also provided are pharmaceutical compositions containing this vector and uses therefor in lowering cholesterol and/or treating familial hypercholesterolemia.

The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and/or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.

A compound of the formula (1):

wherein

• • m, n and p is independently an integer of 0 to 4 with the proviso that 3≦m+n≦8; X is the formula: NR⁴, etc.; R¹, R³ and R⁴ are a substituted or unsubstituted aryl group, etc.; R² is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: —SO₂—, etc.; and Z is an oxygen atom, etc.;

or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.

The invention belongs to the field of new auxiliary materials and new dosage forms for pharmaceutical preparations and relates to design and application of a drug delivery system taking endogenous apolipoprotein E as a target spot, comprising design and synthesis of a carrier structure modifying a hydrophobic material by virtue of a polyethylene glycol (PEG) connecting arm by dihydroartemisinin (DHA). The used carrier material actively customizing apolipoprotein E takes DHA as a target head, PEG as a connecting arm and the hydrophobic material (such as PLGA) as an anchoring part. A nano delivery preparation prepared from the carrier material can encapsulate multiple anti-tumor drugs, and by virtue of interaction of the apolipoprotein combined with DHA on the surface of the nano delivery preparation and low density lipoprotein receptors (LDLr) highly expressed by tumor cells, multiple biological transmission barriers are overcome, and accumulation of nano particles at tumor parts as well as intake and anti-tumor activity in the tumor cells are effectively improved. The nano delivery preparation has good stability, high safety and excellent targeting capability, can be applied to intravenous injection and has a relatively great market application prospect.

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

The invention relates to polynucleotides encoding a low density lipoprotein receptor. The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).

The invention relates to extracorporeal methods of analyzing the presence or absence of mutations which cause familial hypercholesterolemia. The inventive methods describe the way in which said mutations can be detected using a DNA sample from an individual and comprising the following: chain reaction of the polymerase with primers which are complementary to the low-density lipoprotein receptor gene; analysis of the amplified product by sequencing; restriction analysis; single strand conformation polymorphism techniques; heteroduplex analysis and analysis of a device on top of a biochip glass support on which oligonucleotide probes are disposed, which can be used to detect the aforementioned mutations in the DNA.

The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-density lipoprotein receptor, apolipoprotein-A1, superoxide dismutase-2, and catalase, characterised in that: the composition comprising acylated steryl glucoside.

The invention belongs to the field of pharmacy, and relates to an application of quercetin-3-O-(6''-O-alpha-L-rhamnose)-beta-D-glucose-O-beta-D-glucoside (ZYZ-772) in lipid metabolism regulation, especially an application in the preparation of drugs for treating diseases related with lipid metabolism. The results of in-vivo and in-vitro experiments show that the lipid metabolism adjusting effect of the provided compound is better than that of quercetin with a mother nucleus structure of the compound; and the results show that the provided compound can adjust the blood lipid level, reduces the aggregation of lipid in the liver so as to prevent fatty liver, and can adjust the lipid through increasing the activity of low density lipoprotein receptor (LDLR) and promoting the expression of cholesterol adjusting element binding protein-2 (SREBP-2). The compound ZYZ has a prominent adjusting effect on lipid metabolism, and can be used to prepare drugs for treating diseases related with lipid metabolism.